Cost-Effectiveness Analysis of Xiyanping Injection (Andrographolide Sulfonate) for Treatment of Adult Community Acquired Pneumonia: A Retrospective, Propensity Score-Matched Cohort Study

Xiyanping injection (andrographolide sulfonate) has shown clinical effects on community acquired pneumonia. However, there is little known about the effectiveness and costs of combining Xiyanping injection with conventional treatment on adult community acquired pneumonia in daily practice. The aim of this study was to evaluate the cost-effectiveness of combining Xiyanping injection with conventional treatment for treatment of adult community acquired pneumonia by comparing with conventional treatment from a societal perspective. Using retrospective cohort method, this study demonstrates that Xiyanping injection combined with conventional treatment is superior to conventional treatment for patients using cephalosporins and antibiotics under the effectiveness index of length of hospital stay and is more cost-effective.

[1]  M. Shestakova,et al.  [A 20-year prospective follow-up study to evaluate the development of retinopathy and nephropathy after the onset of type 1 diabetes mellitus: Contribution of glycemic control and metabolic memory]. , 2017, Terapevticheskii arkhiv.

[2]  O. V. Ruina,et al.  [Analysis of the efficiency of antimicrobial treatment for community-acquired pneumonia in clinical practice]. , 2017, Terapevticheskii arkhiv.

[3]  Yan Li,et al.  Disease burden of community acquired pneumonia among children under 5 y old in China: A population based survey , 2017, Human vaccines & immunotherapeutics.

[4]  Li Demin,et al.  xi yan ping zhu she ye fu zhu zhi liao she qu huo de xing fei yan 60 li lin chuang guan cha , 2013 .

[5]  Suying Li,et al.  Clinical and Economic Burden of Community‐Acquired Pneumonia in the Medicare Fee‐for‐Service Population , 2012, Journal of the American Geriatrics Society.

[6]  R. Lobmann,et al.  Mean cell volume of neutrophils and monocytes compared with C‐reactive protein, interleukin‐6 and white blood cell count for prediction of sepsis and nonsystemic bacterial infections , 2009, International journal of laboratory hematology.

[7]  A. Anzueto,et al.  A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. , 2008, Chest.

[8]  M. Turley,et al.  Economic cost of community-acquired pneumonia in New Zealand adults. , 2004, The New Zealand medical journal.

[9]  T. Fukui,et al.  [Cost-effectiveness analysis of ambulatory treatment for adult patients with community-acquired pneumonia: according to Japanese Respiratory Society guidelines]. , 2002, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society.

[10]  W. Tan,et al.  Hospitalised low-risk community-acquired pneumonia: outcome and potential for cost-savings. , 1999, Annals of the Academy of Medicine, Singapore.